Press review (May 21, 2011) – Revue de presse (21 mai 2011)

MetMAb in combination with Tarceva (erlotinib) doubled the time people with lung cancer lived without their disease getting worse

Roche’s investigational personalised medicine showed promising final Phase II results in people with a form of lung cancer.

Insciences Organisation

http://insciences.org/article.php?article_id=10124

Pfizer submits files for NSCLC drug crizotinib

The company says that its New Drug Application for crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, has been accepted for filing and granted priority review status by the US Food and Drug Administration.

By Kevin Grogan. In Pharma Times

http://www.pharmatimes.com/Article/11-05-18/Pfizer_submits_files_for_NSCLC_drug_crizotinib.aspx

Coffee seems to lower the risk of lethal prostate cancer

Drinking coffee is a fine way to start the day, many men would agree. For those worried about prostate cancer, it appears to be a great way to start the day.

By Marissa Cevallos. In Los Angeles Times

http://www.latimes.com/health/boostershots/la-heb-prostate-cancer-20110518,0,5881134.story

US cancer drug spending to jump through 2013-report

U.S. spending on cancer drugs could rise at least 10 percent a year through 2013, fueled by use of effective -- and expensive -- new therapies used over longer periods, according to a report released on Wednesday. Oncology medicines are on track to become the third-largest contributor to increases in drug spending by 2015, up from seventh last year, according to the report from large pharmacy benefit manager Medco Health Solutions Inc.

By Lewis Krauskopf & Lisa Von Ahn. Reuters

http://www.reuters.com/article/2011/05/18/medco-drugs-spending-idUSN1826570920110518

Cancer Stocks Focus of ASCO Abstract Release

Investors got their first look at thousands of cancer drug research abstracts released Wednesday night by the American Society of Clinical Oncology (ASCO) in advance of its closely watched annual meeting.

By Adam Feuerstein. In TheStreet.com

http://www.thestreet.com/story/11122077/1/cancer-stocks-focus-of-asco-abstract-release.html?cm_ven=GOOGLEN

Smoking Raises Odds for Cancer in Women Already at High Risk

Lung, colon tumors more likely when habit lasts for years, study finds.

In U.S. News & World Report

http://health.usnews.com/health-news/family-health/cancer/articles/2011/05/19/smoking-raises-odds-for-cancer--in-women-already-at-high-risk

Amgen's Xgeva (denosumab) delays prostate cancer bone pain

A clinical trial of Amgen Inc's bone drug, Xgeva, found that it can significantly delay the time it takes for prostate cancer to cause bone pain -- a finding the company believes will help boost the drug's market potential.

By Deena Beasley, Steve Orlofsky. Reuters

http://www.reuters.com/article/2011/05/17/us-amgen-xgeva-idUSTRE74G4LT20110517

FDA Approves Sunitinib for Pancreatic Neuroendocrine Tumors

The US Food and Drug Administration (FDA) has approved sunitinib malate (Sutent, Pfizer, Merck) for the treatment of pancreatic neuroendocrine tumors (NETs), making it the first antivascular endothelial growth factor receptor (anti-VEGF) therapy for this disease.

By Roxanne Nelson. In Medscape

http://www.medscape.com/viewarticle/743167

More information is available on the FDA Web site (http://www.fda.gov/).

Le taux de mortalité est en baisse pour la plupart des cancers 

Bonnes nouvelles dans le domaine du cancer au Québec: le taux d'incidence du cancer n'est pas en hausse et le taux de mortalité est en baisse «pour la plupart des cancers». La Société canadienne du cancer a même observé une «chute marquée» du taux de mortalité pour certains cancers..

De Lia Lévesque. Dans La Presse Canadienne

http://www.google.com/hostednews/canadianpress/article/ALeqM5gJ51EkakCYO8echiiB626vjRFUGQ?docId=6884518

Cancer utérin: un dépistage tous les trois ans suffit 

Les deux tests combinés de dépistage du cancer du col de l'utérus sont assez fiables pour n'être effectués que tous les trois ans, et non chaque année, chez les femmes de plus de 30 ans, confirme une étude publiée mercredi aux Etats-Unis.

AFP

http://www.google.com/hostednews/afp/article/ALeqM5hoie4vO_c_NGDGZmophYVbXA6YBg?docId=CNG.56a061de96baad08a3f71bb22f4cfb5c.f81

Cancer : une campagne pour changer notre regard sur les malades

Même si des campagnes de sensibilisation ont déjà été menées ces dernières années et que le taux de mortalité recule, le cancer reste une maladie parasitée par de nombreux préjugés. Des a priori qui, souvent, sont sources d'exclusion pour les personnes atteintes par la maladie.

Dans MaxiSciences

http://www.maxisciences.com/cancer/cancer-une-campagne-pour-changer-notre-regard-sur-les-malades_art14672.html

Le clip : http://www.maxisciences.com/cancer/le-ministere-de-la-sante-veut-changer-notre-regard-sur-les-cancers_art14676.html

Des gouttelettes pour détecter l'ADN tumoral

Dans un avenir proche, détecter un cancer sera peut-être possible par une simple analyse de sang ou d'urine. En effet, des biologistes du CNRS, de l'Inserm et des universités Paris Descartes et de Strasbourg viennent de mettre au point une technique capable de déceler les infimes traces d'ADN tumoral présentes dans les fluides biologiques de patients atteints d'un cancer.

CNRS (Communiqué de presse)

http://www2.cnrs.fr/presse/communique/2187.htm